{"commentary":{"count":32,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":12,"x_thread":12,"podcast":8},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06452277\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"SOHO-02","nct_id":"NCT06452277","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=soho-02-nct06452277. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"SOHO-02","arms":[{"description":"Participants will receive sevarbetinib 20 mg BID until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria.","label":"Sevabertinib","type":"EXPERIMENTAL"},{"description":"Participants will receive SoC (pembrolizumab in combination with platinum-based chemotherapy, in 21-day cycles per the approved labels) until disease progression per RECIST v1.1, unacceptable toxicity, or until any other withdrawal criteria. Participants in the SoC arm will have the opportunity to crossover to receive sevabertinib when they experience disease progression.","label":"Standard of care (SoC)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-06-27","type":"ESTIMATED"},"conditions":["Advanced Non-small Cell Lung Cancer, HER2 Mutation"],"enrollment":{"count":555,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Sevabertinib","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Pemetrexed","type":"DRUG"}],"last_update":"2026-09-23","lead_sponsor":"Bayer","official_title":"A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-10-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival (PFS) per RECIST 1.1 as assessed by BICR","timeFrame":"Up to approximately 2 years"}],"references":[],"start_date":{"date":"2024-08-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","url":"https://clinicaltrials.gov/study/NCT06452277"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/soho-02-nct06452277"}